A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Phase of Trial: Phase II
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs Trabectedin (Primary)
- Indications Leiomyosarcoma; Liposarcoma
- Focus Therapeutic Use
- Acronyms TRAVELL
- 09 May 2019 Status changed from recruiting to completed.
- 09 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Jan 2019.
- 02 Mar 2016 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020, according to ClinicalTrials.gov record.